Send PM
Followers 33
Posts 6001
Boards Moderated 0
Alias Born 09/06/2014

Re: 2themoon1 post# 15224

Thursday, 09/08/2022 8:11:07 PM

Thursday, September 08, 2022 8:11:07 PM

Post# of 15258
There's a lot of meat in the 10-Q but nobody brought it up (nobody read it?) so I just stayed silent.

Two items of particular importance in the 10-Q:

"On July 25, 2022, the Company filed a Certificate of Correction with the Secretary of State of Delaware to render null and void ab initio the Reverse Split Amendment and as a result, the Reverse Split was deemed null and void."

" if by October 30, 2022, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva."

Those were two HUGE disclosures, and very positive, IMO. I was wondering why the R/S didn't happen (see post 15217). Now we know!

And Gene is finally admitting that SMI is a joke, which, as anyone who's been here awhile knows, has always been my contention. Frankly, I'm glad to see them go, because those PR's were obviously hype and nonsense, which means they didn't help Gene's ethos. Don't let the screen door hit ya on the way out, SMI.

To those complaining about the delay in starting the clinicals: (a) they updated entry in July to say that the study start date is now Sept. 2022 and the completion date is now September 2023 --

AND (b) the PR about IRB approval in July said they expected to start in 30-60 days.

So the complaining should stop -- they named their start date and they haven't missed it yet.

I'm still a fan of CEO Gene-O. I give him a mulligan on the SMI hype.

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GTHP News